ProductsIntelligenceLicensingAnalyst AccessPricingMethodologyContact
REGULATORY INTELLIGENCE · APAC

India CDSCO Drugs & Medical Devices

Material regulatory developments from Central Drugs Standard Control Organisation are tracked daily by Cresthaven Analytics. Over the last 90 days, 3 material briefs relevant to professionals operating in the healthcare & life sciences sector have been published below. Each brief is sourced directly from the primary regulatory feed, summarized for institutional readers, and scored for materiality.

Recent material activity

A selection of recent published briefs; this is not a complete archive.

  • Sep 23, 2026MATERIAL

    CDSCO issues circular on chronic kidney disease risks linked to unsupervised NSAID and antibiotic use

    India's Central Drugs Standard Control Organisation (CDSCO) issued a circular on September 22, 2026 addressing indiscriminate use of non-steroidal anti-inflammatory drugs (NSAIDs) and antibiotics. The circular identifies…

    Read a full sample brief →
  • Sep 17, 2026MATERIAL

    CDSCO issues public health alert against unauthorised cosmetics products circulating in the Indian market

    India's Central Drugs Standard Control Organisation (CDSCO) issued a public health alert on September 14, 2026, identifying unauthorised cosmetics products as a consumer safety risk. The alert directs the public against …

    Read a full sample brief →
  • Sep 6, 2026MATERIAL

    India CDSCO Drugs & Medical Devices release pending Cresthaven Analytics full analysis: Public Notice: Drug Regulatory and Law Enforcement Agencies Intensify Coordinated Action Against Illegal Manufacture and Distribution of Misbranded Drug

    India CDSCO Drugs & Medical Devices published a regulatory release titled 'Public Notice: Drug Regulatory and Law Enforcement Agencies Intensify Coordinated Action Against Illegal Manufacture and Distribution of Misbrand…

    Read a full sample brief →

Get every India CDSCO Drugs & Medical Devices brief delivered the day it lands

From $149/month

Cresthaven Analytics monitors Central Drugs Standard Control Organisation continuously, applying institutional materiality scoring to every release. Subscribers receive structured briefs via email, portal, and (Professional tier and above) real-time alerts.

View all tiers →